je.st
news
Tag: drug
Study Finds Multiple Myeloma Drug 'Promising'
2015-12-07 20:50:57| Biotech - Topix.net
Merck & Co's immunotherapy Keytruda led to a high response rate for patients with the blood cancer multiple myeloma when added to standard therapy in a small, early stage trial, according to data presented on Monday. The Phase I study tested Keytruda in combination with Celgene's Revlimid and the corticosteroid dexamethasone in patients whose disease had progressed after they had already received several other treatments, including several who were not helped by previous treatment with Revlimid.
Tags: study
multiple
drug
finds
Premarket Biotech Digest: Gilead And HCV Drug Pricing, Relypsa Rumors, Amgen-Merck Collaboration
2015-12-07 17:45:48| Biotech - Topix.net
Our regular management interview will be held on our subscription panel today at 11am EST with Dr Todd Brady, MD, PhD, CEO of Aldeyra . Please buy a discounted subscription to participate in the panel discussion, and other discussions held regularly for subscribers.
Tags: drug
pricing
collaboration
digest
J&J leukemia drug cuts death risk vs. chemo in new patients: study
2015-12-07 03:47:40| Food - Topix.net
Johnson & Johnson's and AbbVie's cancer drug Imbruvica significantly reduced the risk of death and disease progression compared with chemotherapy in previously untreated patients with a type of leukemia in a late stage study, paving the way for an expanded approval of the medicine. In the trial of 269 patients aged 65 and older with chronic lymphocytic leukemia , Imbruvica decreased risk of death by a statistically significant 85 percent compared with the chemotherapy chlorambucil, researchers reported on Sunday.
Alexion: 2 Global Drug Rollouts, But Upside Already Priced In
2015-12-06 11:18:40| Biotech - Topix.net
Alexion is highly overvalued, even assuming best case peak sales projections of $1B for Strensiq, $1B for Kanuma, and $5B for Soliris. Payer risk for high-priced drugs isn't going away and orphan drug companies can't expect to keep getting a free pass.
We must curtail runaway drug prices
2015-12-06 07:12:24| Biotech - Topix.net
In the New England Journal of Medicine, Dr. Peter Bach recently wrote, "Hand clapping for science is now inextricably linked to hand wringing over affordability." This has been demonstrated frequently in the era of personalized medicine, which has offered unprecedented benefits at huge costs.
Tags: prices
drug
runaway
curtail
Sites : [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] next »